TOPIC

TAKEOVER News & Analysis

Morningstar recommends investors reject takeover offer on A-REIT
Stocks
Morningstar recommends investors reject takeover offer on A-REIT
The bid barely exceeds our fair value and is a 10% discount to net tangible asset value.
Adrian Atkins | 09 September 2024
Management turmoil ends for cheap ASX share
Stocks
Management turmoil ends for cheap ASX share
A new CEO and a rejected takeover bid may mean better days ahead for the beaten down share. 
Angus Hewitt | 09 July 2024
Disappointing offer for undervalued ASX share
Stocks
Disappointing offer for undervalued ASX share
Bid from top shareholder 30% less than Morningstar Fair Value Estimate
Shani Jayamanne | 09 April 2024
What is next for Alumina after takeover bid
Stocks
What is next for Alumina after takeover bid
We lower our fair value after bid. 
Mark Taylor | 26 February 2024
Perpetual takeover bid is lower than our intrinsic assessment
Stocks
Perpetual takeover bid is lower than our intrinsic assessment
Washington H. Soul Pattinson bids $3 billion for Perpetual
Shaun Ler | 07 December 2023
Identifying the next ASX takeover target
Stocks
Identifying the next ASX takeover target
M&A activity is set to ramp up. We reveal which ASX companies could be next in line for a takeover offer.
Nicki Bourlioufas | 19 June 2023
Takeover offers: How to know if investors are getting a good deal
Stocks
Takeover offers: How to know if investors are getting a good deal
Several high-profile takeover bids for ASX-listed companies currently hang in the balance. We compare three offers on the table, and how to...
Joshua Peach | 20 April 2023
Revised takeover bid ‘attractive’ for Newcrest investors: Morningstar
Stocks
Revised takeover bid ‘attractive’ for Newcrest investors: Morningstar
The sweetened takeover bid for Newcrest Mining represents better value for investors and appears more likely to proceed, according to one Morningstar...
Joshua Peach | 12 April 2023
Healius takeover bid may face resistance from board and regulators
Stocks
Healius takeover bid may face resistance from board and regulators
The proposed deal to create Australia’s largest pathology provider faces hurdles from the Healius board and regulators, says Morningstar.
Joshua Peach | 20 March 2023
UBS should benefit from Credit Suisse takeover
Stocks
UBS should benefit from Credit Suisse takeover
Credit Suisse shareholders will feel shortchanged, but salvaging at least something is the best outcome under current circumstances.  
Johann Scholtz | 20 March 2023